ABVC BioPharma, Inc. (ABVC)
NASDAQ: ABVC · Real-Time Price · USD
0.524
+0.006 (1.22%)
At close: Dec 20, 2024, 4:00 PM
0.500
-0.024 (-4.52%)
After-hours: Dec 20, 2024, 5:46 PM EST
ABVC BioPharma Employees
As of December 31, 2023, ABVC BioPharma had 19 total employees, including 16 full-time and 3 part-time employees. The number of employees decreased by 4 or -17.39% compared to the previous year.
Employees
19
Change (1Y)
-4
Growth (1Y)
-17.39%
Revenue / Employee
$26,831
Profits / Employee
-$433,848
Market Cap
6.42M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Syra Health | 162 |
| PAVmed | 107 |
| Ainos | 46 |
| Plus Therapeutics | 20 |
| Galecto | 13 |
| Portage Biotech | 7 |
| CNS Pharmaceuticals | 5 |
| Xenetic Biosciences | 4 |
ABVC News
- 10 days ago - ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners - GlobeNewsWire
- 2 months ago - ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners - GlobeNewsWire
- 4 months ago - ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements - GlobeNewsWire
- 8 months ago - AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share - GlobeNewsWire
- 8 months ago - ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M - GlobeNewsWire
- 9 months ago - ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M - GlobeNewsWire
- 9 months ago - ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M - GlobeNewsWire
- 9 months ago - ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine - GlobeNewsWire